AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26749219
Drug: HYD 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HYD 20 to 120 mg
Trial: 26749219
Drug: HYD 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HYD 120 mg once daily
Trial: 26749219
Drug: HYD 30
RxNorm normalized name: sod/pot/Cl/cit/Zn/mag/carbohyd 305 mg-175 mg-70 mg-2.5 gram-2 mg-40 mg-9 gram ORAL POWDER IN PACKET (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HYD 30 mg
Trial: 25069991
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogens (o‐CEE), 0.45 mg/d, with 200 mg of oral progesterone for 12 days per month for 48 months
Trial: 25069991
Drug: Transdermal 17β‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17β‐estradiol (t‐E2), 50 mcg/d, with 200 mg of oral progesterone for 12 days per month for 48 months
Trial: 23179383
Drug: D +
RxNorm normalized name: Liver Desiccated + B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D + 3 progesterone treatment
Trial: 23179383
Drug: D +
RxNorm normalized name: Liver Desiccated + B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D + 4 progesterone treatment
Trial: 19732051
Drug: Tadalafil (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (2.5, 5, 10, 20 mg)
Trial: 18044196
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy combined with other Cognitive‐Behavioral Therapy (CBT) components
Trial: 9489976
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg mibefradil once daily for 2 weeks
Trial: 9489976
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg mibefradil once daily for 2 additional weeks
Trial: 31883845
Drug: Brodalumab 140
RxNorm normalized name: brodalumab 140 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodalumab 140 mg (n = 46)
Trial: 31883845
Drug: Brodalumab 210
RxNorm normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodalumab 210 mg (n = 41)
Trial: 28012190
Drug: Salicylic acid
RxNorm normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salicylic acid patches (Callívoro Marthand®)
Trial: 23329886
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (tidal volume 8 ml/kg, frequency 12/min)
Trial: 23329886
Drug: Group L
RxNorm normalized name: Blood group Lewis alpha-4-fucosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group L (tidal volume 6 ml/kg, frequency 16/min)
Trial: 21262922
Drug: Postoperative antibacterials
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative antibacterials (treatment indication)
Trial: 18199726
Drug: Buccal mucosa
RxNorm normalized name: Diazepam 5 MG Buccal mucosa Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal mucosa cells (BMC) harvested at baseline and 3 days after baseline.
Trial: 18199726
Drug: Leukocytes collected
RxNorm normalized name: interferon alfa-3n,human leukocyte derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocytes collected in heparin and EDTA.
Trial: 16600934
Drug: Glutamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (0.5 g . kg(‐1) . d(‐1))
Trial: 16600934
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid mixture (0.8 g . kg(‐1) . d(‐1))
Trial: 15000437
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Glyburide and Metformin
Trial: 11345687
Drug: Ketoprofen lysinate
RxNorm normalized name: ketoprofen lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen lysinate solution (160 mg in 100 ml, twice a day for seven days)
Trial: 11345687
Drug: Benzidamine hydrochloride
RxNorm normalized name: benzydamine
DrugBank: Benzydamine (DB09084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzidamine hydrochloride (15 ml, twice a day for seven days)
Trial: 8868980
Drug: Pimobendan 5
RxNorm normalized name: pimobendan 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimobendan 5 mg daily
Trial: 1729854
Drug: Pimobendan 10
RxNorm normalized name: pimobendan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimobendan 10 mg daily
Trial: 30537550
Drug: Continuous TKI
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous TKI with chemotherapy (nontransplant arm)
Trial: 29898217
Drug: Topical ozenoxacin
RxNorm normalized name: ozenoxacin Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ozenoxacin cream 1%
Trial: 22150098
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (8 ounces daily for 1 month)
Trial: 22150098
Drug: White wine
RxNorm normalized name: White wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White wine (8 ounces daily for 1 month)
Trial: 20886510
Drug: CoQ(10) treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ(10) treatment (1200 mg/day for 60 days)
Trial: 17302514
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg intravenous iron sucrose
Trial: 17302514
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n=5) without iron treatment
Trial: 10435727
Drug: Busulphan at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busulphan at 600 mg/m2 with cyclophosphamide alone (Group B)
Trial: 10435727
Drug: Busulphan at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busulphan at 16 mg/kg with cyclophosphamide and ATG (Group A)
Trial: 10435727
Drug: Busulphan at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busulphan at 600 mg/m2 (Group B)
Trial: 10435727
Drug: Busulphan at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busulphan at 16 mg/kg (Group A)
Trial: 8574032
Drug: Gd zeolite
RxNorm normalized name: zeolite A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gd zeolite oral suspension (250 to 1500 mL; 6 to 60 micrograms of Gd+3/mL) administered before and after MRI
Trial: 8574032
Drug: Gd zeolite
RxNorm normalized name: zeolite A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gd zeolite oral suspension
Trial: 7428408
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg mianserin
Trial: 375686
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg mianserin
Trial: 7428408
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg sustained-release amitriptyline
Trial: 19827484
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied hydrogel containing 0.5% morphine plus subcutaneous placebo infusion
Trial: 19827484
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel plus subcutaneous infusion of 5mg morphine
Trial: 19827484
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel plus subcutaneous placebo infusion
Trial: 9626795
Drug: Carboplatin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (600 mg/m2) and Cyclophosphamide (1,500 mg/m2) with filgrastim
Trial: 9626795
Drug: Carboplatin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (300 mg/m2) and Cyclophosphamide (600 mg/m2) without filgrastim
Trial: 9626795
Drug: Carboplatin and
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin and Cyclophosphamide at 2.5 times standard dose with filgrastim
Trial: 9626795
Drug: Carboplatin and
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin and Cyclophosphamide at standard dose without filgrastim
Trial: 9626795
Drug: Carboplatin and
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin and Cyclophosphamide at 2.5 times standard dose
Trial: 8055283
Drug: Systemic brachytherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic brachytherapy with radiolabeled antibodies
Trial: 30772342
Drug: Diclofenac suppositories
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac suppositories (50 mg) + Sublingual isosorbide dinitrate (5 mg)
Trial: 30772342
Drug: Diclofenac suppositories
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac suppositories (50 mg)
Trial: 25801162
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine (0.3 mg/kg) with midazolam (0.02 mg/kg) and fentanyl (1 μg/kg)
Trial: 25801162
Drug: Midazolam (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.02 mg/kg) and fentanyl (1 μg/kg) with placebo (0.9% sodium chloride)
Trial: 23686563
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day elemental iron supplements
Trial: 23686563
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day elemental iron + 500 mg/day ascorbic acid
Trial: 22080318
Drug: Low fat
RxNorm normalized name: Low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fat chocolate milk (1 g carbohydrate per kg body weight)
Trial: 17407641
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g paracetamol plus 130 mg caffeine
Trial: 9476036
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g paracetamol alone
Trial: 17407641
Drug: 130 mg
RxNorm normalized name: pectin 130 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 130 mg caffeine alone
Trial: 9647338
Drug: tolrestat (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolrestat (200 mg a day)
Trial: 2582720
Drug: Vasopressin infusion
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressin infusion at a rate of 2 i.u./h for 1 h, followed by 4 i.u./h for a further hour
Trial: 29319721
Drug: Vasopressin infusion
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressin infusion
Trial: 23189924
Drug: Negotiated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negotiated treatment plan
Trial: 23189924
Drug: No negotiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No negotiated treatment plan
Trial: 23189924
Drug: Negotiated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negotiated treatment plan at fewer than three time points
Trial: 21241290
Drug: MgCl(2) 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MgCl(2) 2.5 g daily
Trial: 21241290
Drug: Placebo (inactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (inactive solution)
Trial: 18055171
Drug: Systemic anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic anticoagulation with intravenous heparin
Trial: 9706914
Drug: Isotonic sodium
RxNorm normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic sodium chloride solution (control)
Trial: 24677033
Drug: HQK-1001 (2,2-dimethylbutyrate)
RxNorm normalized name: 2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HQK-1001 (2,2-dimethylbutyrate) at 15 mg/kg twice daily for 48 weeks
Trial: 15339465
Drug: Xiangdan Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiangdan Injection plus standard treatment for coronary heart disease
Trial: 15339465
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for coronary heart disease (Control)
Trial: 9817278
Drug: Two cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two cycles of MCV chemotherapy before concurrent cisplatin and radiation therapy (arm 1, n=61)
Trial: 9817278
Drug: Standard induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard induction therapy (arm 2, n=62)
Trial: 7654489
Drug: Intravenous dexfenfluramine
RxNorm normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexfenfluramine (d-F) 15.5 mg base infused over 3 h
Trial: 7654489
Drug: Oral dexfenfluramine
RxNorm normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dexfenfluramine (d-F) 25.9 mg base in capsules
Trial: 7654489
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and oral dexfenfluramine (d-F)
Trial: 30864006
Drug: PPB +
RxNorm normalized name: Piperacillin plus Tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPB + IRLA (3.0 mL of 2% lidocaine injected at the bilateral pelvic plexus)
Trial: 30864006
Drug: PNB +
RxNorm normalized name: PNB
DrugBank: P-nitrobiphenyl (DB12300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNB + IRLA (3.0 mL of 2% lidocaine injected at both periprostatic nerves)
Trial: 25847131
Drug: Alteplase 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase 0.1 mg/kg twice a day on days 1 and 3 or days 2 and 4
Trial: 23667063
Drug: Rituximab 375
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m(2)
Trial: 16176939
Drug: DMPA-SC 104
RxNorm normalized name: DMPA
DrugBank: Zytron (DB11768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMPA-SC 104 (104 mg/0.65 ml every 3 months)
Trial: 16176939
Drug: Leuprolide (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide (3.75 mg monthly or 11.25 mg every 3 months)
Trial: 9170576
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy (goserelin acetate depot 3.6 mg subcutaneously every 4 weeks)
Trial: 9170576
Drug: Chemohormonal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemohormonal therapy (goserelin acetate depot 3.6 mg subcutaneously and cyclophosphamide 1000 mg/m2 intravenously every 4 weeks)
Trial: 29525541
Drug: Chemohormonal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemohormonal therapy
Trial: 1951075
Drug: Low-dose sotalol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sotalol (40 mg every 6 hours for 6 days)
Trial: 7230984
Drug: Oral antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antimicrobial bowel preparation with metronidazole and kanamycin
Trial: 7230984
Drug: Parenteral antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral antibiotic prophylaxis with metronidazole and kanamycin
Trial: 31919035
Drug: Mini-goal games
RxNorm normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini-goal games (MG)
Trial: 25875795
Drug: Single-step treatment
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-step treatment
Trial: 25875795
Drug: 2-step treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-step treatment
Trial: 23571173
Drug: Two-dose inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose inactivated hepatitis A vaccine (Healive(®))
Trial: 23571173
Drug: One-dose inactivated
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-dose inactivated hepatitis A vaccine (Healive(®))
Trial: 23571173
Drug: Attenuated vaccine
RxNorm normalized name: Chikungunya live attenuated vaccine, 0.5 mL, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attenuated vaccine B
Trial: 23571173
Drug: Attenuated vaccine
RxNorm normalized name: Chikungunya live attenuated vaccine, 0.5 mL, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attenuated vaccine C
Trial: 23571173
Drug: Attenuated vaccine
RxNorm normalized name: Chikungunya live attenuated vaccine, 0.5 mL, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attenuated vaccine A
Trial: 21819749
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of i.v. dexamethasone preoperatively and again after 24 and 48 hours after surgery
Trial: 21819749
Drug: Three pseudoephedrine
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three pseudoephedrine tablets (60 mg) per day for 1 week
Trial: 21819749
Drug: Three pseudoephedrine
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three pseudoephedrine tablets (60 mg) per day for 2 weeks
Trial: 20068365
Drug: alpha-interferon 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-interferon 0.5 million IU b.i.d., thalidomide (100 mg b.i.d. reduced to 100 mg daily), or celecoxib (400 mg daily reduced to 200 mg)
Trial: 20068365
Drug: two-drug combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two-drug combinations of alpha-interferon, thalidomide or celecoxib
Trial: 11281338
Drug: Trandolapril 2
RxNorm normalized name: trandolapril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril 2 mg and verapamil 180 mg
Trial: 11281338
Drug: Trandolapril 2
RxNorm normalized name: trandolapril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril 2 mg and amlodipine 5 mg
Trial: 9004107
Drug: Trandolapril 2
RxNorm normalized name: trandolapril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril 2 mg
Trial: 9400948
Drug: G-CSF given
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF given daily on days 7-17 to all patients
Trial: 24931756
Drug: Parenteral Dipeptiven(®)
RxNorm normalized name: palmitoyl dipeptide-7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral Dipeptiven(®) supplementation of 0.5 g/kg/day
Trial: 23609487
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy‐based self‐help program delivered by the Internet with e‐mail guidance
Trial: 19176222
Drug: Schema-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schema-focused therapy (SFT) combined with treatment-as-usual (TAU)
Trial: 28066274
Drug: Treatment-as-usual (TAU)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (TAU) alone
Trial: 17522560
Drug: Oral haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral haloperidol
Trial: 15474895
Drug: D-cycloserine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine (50 mg p.o. QD)
Trial: 12126875
Drug: Buspirone 30
RxNorm normalized name: busPIRone 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 30 mg administered orally
Trial: 9576366
Drug: Intraperitoneal calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal calcitriol (5.4 ± 1.2 microg/week, maximum 6.6 ± 1.5 microg/week) administered twice per week before bedtime.
Trial: 2651014
Drug: 4.5 mg
RxNorm normalized name: phenol 14.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 mg ergoloid mesylates per day
Trial: 144507
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg D-penicillamine (DP)
Trial: 144507
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg D-penicillamine (DP)
Trial: 31422458
Drug: IV PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV PCA oxycodone
Trial: 28860712
Drug: Oral oxycodone
RxNorm normalized name: oxycodone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oxycodone
Trial: 25432952
Drug: 125 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 µg peginterferon beta‐1a every 2 weeks
Trial: 25432952
Drug: 125 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 µg peginterferon beta‐1a every 4 weeks
Trial: 21288774
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor and switch to second-line at 1000 copies per mL (PI-low)
Trial: 21288774
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor and switch at 30,000 copies per mL (PI-higher)